View Item 

Show simple item record

Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
dc.contributor.authorCuker, A.en_US
dc.contributor.authorPtashkin, B.en_US
dc.contributor.authorKonkle, B. A.en_US
dc.contributor.authorPipe, Steven W.en_US
dc.contributor.authorWhinna, H. C.en_US
dc.contributor.authorZheng, X. L.en_US
dc.contributor.authorCines, D. B.en_US
dc.contributor.authorPollak, E. S.en_US
dc.date.accessioned2010-06-01T21:31:44Z
dc.date.available2010-06-01T21:31:44Z
dc.date.issued2009-01en_US
dc.identifier.citationCUKER, A.; PTASHKIN, B.; KONKLE, B. A.; PIPE, S. W.; WHINNA, H. C.; ZHENG, X. L.; CINES, D. B.; POLLAK, E. S. (2009). "Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time." Journal of Thrombosis and Haemostasis 7(1): 80-86. <http://hdl.handle.net/2027.42/74583>en_US
dc.identifier.issn1538-7933en_US
dc.identifier.issn1538-7836en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74583
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19017257&dopt=citationen_US
dc.format.extent264178 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights© 2009 International Society on Thrombosis and Haemostasisen_US
dc.subject.otherActivated Partial Thromboplastin Timeen_US
dc.subject.otherAnti-factor Xaen_US
dc.subject.otherFactor Xa Inhibition Assayen_US
dc.subject.otherUnfractionated Heparinen_US
dc.titleInterlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin timeen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum† Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationother* Department of Medicine anden_US
dc.contributor.affiliationother† Departments of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PAen_US
dc.contributor.affiliationother§ Department of Pathology, University of North Carolina, Chapel Hill, NCen_US
dc.contributor.affiliationother¶ Department of Pathology, Children’s Hospital of Philadelphia, Philadelphia, PA, USAen_US
dc.identifier.pmid19017257en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74583/1/j.1538-7836.2008.03224.x.pdf
dc.identifier.doi10.1111/j.1538-7836.2008.03224.xen_US
dc.identifier.sourceJournal of Thrombosis and Haemostasisen_US
dc.identifier.citedreferenceChiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171 – 84.en_US
dc.identifier.citedreferenceBasu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324 – 7.en_US
dc.identifier.citedreferenceShapiro GA, Huntzinger SW, Wilson JE. Variation among commercial activated partial thromboplastin time reagents in response to heparin. Am J Clin Pathol 1977; 67: 477 – 80.en_US
dc.identifier.citedreferenceKitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996; 49: 10 – 14.en_US
dc.identifier.citedreferenceD’Angelo A, Seveso MP, D’Angelo SV, Gilardoni F, Dettori AG, Bonini P. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Implications in heparin monitoring by APTT. Am J Clin Pathol 1990; 94: 297 – 306.en_US
dc.identifier.citedreferenceKitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75: 734 – 9.en_US
dc.identifier.citedreferenceBates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001; 161: 385 – 91.en_US
dc.identifier.citedreferenceBrill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104 – 9.en_US
dc.identifier.citedreferenceOlson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782 – 98.en_US
dc.identifier.citedreferenceHirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 141S – 59S.en_US
dc.identifier.citedreferenceToulon P, Boutiere B, Horellou MH, Trzeciak MC, Samama MM. Monitoring heparin therapy using activated partial thromboplastin time – results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin. Thromb Haemost 1998; 80: 104 – 8.en_US
dc.identifier.citedreferenceSmythe MA, Koerber JM, Westley SJ, Nowak SN, Begle RL, Balasubramamiam M, Mattson JC. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol 2001; 115: 148 – 55.en_US
dc.identifier.citedreferenceBaker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997; 157: 2475 – 9.en_US
dc.identifier.citedreferenceKitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000; 11: 137 – 44.en_US
dc.identifier.citedreferenceKovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21: 55 – 60.en_US
dc.identifier.citedreferenceIgnjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennett M, Horton S, Shann F, Lane G, Ross-Smith M, Monagle P. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res 2007; 120: 347 – 51.en_US
dc.identifier.citedreferencevan den Besselaar AM, Meeuwisse-Braun J, Jansen-Gruter R, Bertina RM. Monitoring heparin therapy by the activated partial thromboplastin time – the effect of pre-analytical conditions. Thromb Haemost 1987; 57: 226 – 31.en_US
dc.identifier.citedreferenceAdcock D, Kressin D, Marlar RA. The effect of time and temperature variables on routine coagulation tests. Blood Coagul Fibrinolysis 1998; 9: 463 – 70.en_US
dc.identifier.citedreferenceLevine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49 – 56.en_US
dc.identifier.citedreferenceCrafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 1937; 79: 407 – 26.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1538-7836.2008.03224.x.pdf
Size:
257.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.